As a spin-off from the MDC Berlin, OMEICOS has continued a close collaboration with the working groups of OMEICOS’ co-founders Dr. Wolf-Hagen Schunck and Dr. Dominik Müller since its foundation. Joint research activities helped to further elucidate the molecular mode of action of natural Cytochrome P450-dependent metabolites of omega-3 fatty acids and their synthetic analogs activating a novel protective pathway in cardiomyocytes and other cell types.
University of Alberta
OMEICOS is working closely together with the research group of John Seubert to investigate the effect of OMEICOS’ compounds in indications, associated with mitochondrial dysfunction. Dr. Seubert’s laboratory research is focused on investigating the role of CYP epoxygenase metabolites in maintaining tissue homeostasis and reducing injury with a special focus on cardioprotection, ischemia-reperfusion, mitochondria, toxicology, the cytochrome P450 system and mechanisms of cellular death.
OMEICOS is working closely together with the research group of Dobromir Dobrev to investigate the effect of OMEICOS’ compounds on Calcium homeostasis and related signal transduction processes. Dr. Dobrev’s laboratory research is focused on clarifying how specific molecular alterations in cardiac cells and disease-related remodeling cause electrical instability.
Lipidomix GmbH is a specialized lipid analysis lab which conducts high-throughput lipidomic analysis, in particular eicosanoids. It is based on rapid-resolution-HPLC in combination with triple quad tandem mass spectrometry. Lipidomix develops and validates analysis methods for areas in the life sciences, food monitoring, forensics and others.
Omegametrix is an international reference laboratory for the determination of the so called HS-Omega-3 Index®, a standardized method for erythrocyte fatty acid analysis. Dr. Clemens von Schacky, Head of Preventive Cardiology at the LMU Munich, together with Prof. W.S. Harris, Sanford University established the HS-Omega-3 Index® and founded Omegametrix in Martinsried, Germany, in 2007.
Biotronik is a leading medical device company that has been developing innovative cardiovascular and endovascular solutions for more than 50 years. Biotronik is headquartered in Berlin, Germany, and represented in over 100 countries. OMEICOS had implemented Biotronik’s insertable cardiac monitor BioMonitor 2 into the study design of the Phase 2 clinical trial of OMT-28 in persistent Atrial Fibrillation to accurately detect and monitor arrhythmias.